Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price gapped up prior to trading on Friday . The stock had previously closed at $18.70, but opened at $20.35. Oculis shares last traded at $20.41, with a volume of 64,061 shares changing hands.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on OCS shares. Chardan Capital reiterated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Oculis presently has a consensus rating of “Buy” and an average price target of $28.80.
Get Our Latest Stock Report on OCS
Oculis Stock Up 10.8 %
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
- Five stocks we like better than Oculis
- Stock Dividend Cuts Happen Are You Ready?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How to Choose Top Rated Stocks
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
- Expert Stock Trading Psychology Tips
- 3 EV Stocks Offering Unique Alternatives to Tesla
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.